Immunovant Stock Performance
| IMVT Stock | USD 26.89 0.02 0.07% |
The company retains a Market Volatility (i.e., Beta) of 1.09, which attests to a somewhat significant risk relative to the market. Immunovant returns are very sensitive to returns on the market. As the market goes up or down, Immunovant is expected to follow. At this point, Immunovant has a negative expected return of -0.2%. Please make sure to check out Immunovant's jensen alpha, skewness, as well as the relationship between the Skewness and day typical price , to decide if Immunovant performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Immunovant has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
Actual Historical Performance (%)
One Day Return 0.3 | Five Day Return 2.04 | Year To Date Return (34.84) | Ten Year Return 171.06 | All Time Return 171.06 |
1 | Disposition of 4847 shares by Pande Atul of Immunovant at 40.46 subject to Rule 16b-3 | 09/13/2024 |
2 | Disposition of 4460 shares by Salzmann Peter of Immunovant at 29.56 subject to Rule 16b-3 | 10/09/2024 |
3 | Immunovants chief medical officer William Macias sells 91,782 in stock | 10/18/2024 |
4 | Disposition of 150000 shares by Geffner Michael of Immunovant at 18.06 subject to Rule 16b-3 | 10/22/2024 |
5 | Disposition of 2740 shares by Jay Stout of Immunovant at 29.53 subject to Rule 16b-3 | 10/23/2024 |
6 | Immunovants chief medical officer sells 94,171 in stock | 10/25/2024 |
7 | Disposition of 2362 shares by Macias William L. of Immunovant at 29.64 subject to Rule 16b-3 | 10/31/2024 |
8 | Immunovants Q2 Loss Wider Than Expected, Pipeline in Focus | 11/08/2024 |
9 | ARMISTICE CAPITAL, LLC Acquires New Stake in Trevena Inc | 11/15/2024 |
10 | Insider Trading | 11/18/2024 |
11 | Immunovant stock hits 52-week low at 24.66 amid market shifts - Investing.com | 11/19/2024 |
12 | Disposition of 16692 shares by Salzmann Peter of Immunovant at 25.45 subject to Rule 16b-3 | 11/20/2024 |
13 | Immunovant CFO Eva Renee Barnett sells 106,228 in stock | 11/22/2024 |
14 | Have Immunovant Insiders Been Selling Stock | 11/25/2024 |
| Begin Period Cash Flow | 376.5 M |
Immunovant |
Immunovant Relative Risk vs. Return Landscape
If you would invest 3,135 in Immunovant on August 28, 2024 and sell it today you would lose (446.00) from holding Immunovant or give up 14.23% of portfolio value over 90 days. Immunovant is currently does not generate positive expected returns and assumes 2.7531% risk (volatility on return distribution) over the 90 days horizon. In different words, 24% of stocks are less volatile than Immunovant, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Immunovant Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Immunovant's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Immunovant, and traders can use it to determine the average amount a Immunovant's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0734
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | IMVT |
Estimated Market Risk
| 2.75 actual daily | 24 76% of assets are more volatile |
Expected Return
| -0.2 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.07 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Immunovant is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Immunovant by adding Immunovant to a well-diversified portfolio.
Immunovant Fundamentals Growth
Immunovant Stock prices reflect investors' perceptions of the future prospects and financial health of Immunovant, and Immunovant fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Immunovant Stock performance.
| Return On Equity | -0.92 | ||||
| Return On Asset | -0.55 | ||||
| Current Valuation | 3.47 B | ||||
| Shares Outstanding | 146.78 M | ||||
| Price To Book | 8.78 X | ||||
| EBITDA | (269.98 M) | ||||
| Net Income | (259.34 M) | ||||
| Cash And Equivalents | 427.2 M | ||||
| Cash Per Share | 3.66 X | ||||
| Total Debt | 138 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 21.48 X | ||||
| Book Value Per Share | 3.06 X | ||||
| Cash Flow From Operations | (214.23 M) | ||||
| Earnings Per Share | (2.21) X | ||||
| Market Capitalization | 3.95 B | ||||
| Total Asset | 666.37 M | ||||
| Retained Earnings | (825.68 M) | ||||
| Working Capital | 617.16 M | ||||
About Immunovant Performance
Assessing Immunovant's fundamental ratios provides investors with valuable insights into Immunovant's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Immunovant is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Capital Employed | (0.46) | (0.02) | |
| Return On Equity | (0.42) | (0.02) |
Things to note about Immunovant performance evaluation
Checking the ongoing alerts about Immunovant for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Immunovant help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Immunovant generated a negative expected return over the last 90 days | |
| Immunovant has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (259.34 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Immunovant currently holds about 427.2 M in cash with (214.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.66. | |
| Immunovant has a frail financial position based on the latest SEC disclosures | |
| Roughly 56.0% of the company shares are held by company insiders | |
| Latest headline from simplywall.st: Have Immunovant Insiders Been Selling Stock |
- Analyzing Immunovant's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Immunovant's stock is overvalued or undervalued compared to its peers.
- Examining Immunovant's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Immunovant's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Immunovant's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Immunovant's stock. These opinions can provide insight into Immunovant's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Immunovant Stock Analysis
When running Immunovant's price analysis, check to measure Immunovant's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunovant is operating at the current time. Most of Immunovant's value examination focuses on studying past and present price action to predict the probability of Immunovant's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunovant's price. Additionally, you may evaluate how the addition of Immunovant to your portfolios can decrease your overall portfolio volatility.